158147-50-3

Basic information

• Product Name: 1H-1,2,4-Triazole-1-butanoic acid, phenylmethyl ester
• CAS NO: 158147-50-3
• Molecular Formula: C13H15N3O2
• Molecular Weight: 245.281
• Mol File: 158147-50-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-1,2,4-Triazole-1-butanoic acid, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-1,2,4-Triazole-1-butanoic acid, phenylmethyl ester(158147-50-3)
• EPA Substance Registry System: 1H-1,2,4-Triazole-1-butanoic acid, phenylmethyl ester(158147-50-3)

Safety Data

• Hazardous Substances Data: 158147-50-3(Hazardous Substances Data)

Upstream product

• 288-88-0 1,2,4-Triazole 
• 126430-46-4 benzyl 4-bromobutanoate 

Downstream Products

• 158147-52-5 4-(1,2,4-triazol-1-yl)butyric acid 

Relevant articles and documents

Studies on disease-modifying antirheumatic drugs: Synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect

In the course of our study aimed at developing new types of DMARDs (disease-modifying antirheumatic drugs), we found that quinoline derivative 1a had a potent anti-inflammatory effect in an adjuvant arthritis (AA) rat model, starting from the potent bone resorption inhibitors justicidins as the lead compounds. Further modification of 1a was performed, and various quinoline and quinazoline derivatives having a heteroaryl moiety on the alkyl side chain at the 2-position of the skeleton were prepared. These compounds were evaluated for antiinflammatory effects using the AA rat model. Most of these compounds, especially those having an imidazole or a triazole moiety on the 2-alkyl chain, exhibited a potent effect. Among the compounds synthesized, ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1- yl-methyl)quinoline-3-carboxylate (12d), having an ED50 value of 2.6 mg/kg/day (anti-inflammatory effect in an AA rat model, po), was selected as a candidate for further investigation. In vitro, 12d inhibited mitogen- induced proliferation at 10-7-10-5 M but not prostaglandin E2 production at 10-5 M. Moreover, 12d preferentially inhibited the IFN-γ production by Th1-type clones over the IL-4 production by Th2-type clones. This preferential suppression of Th1 cytokine production is considered the essential immunomodulating action of 12d for the present. Synthesis and structure-activity relationships for this novel series of quinoline and quinazoline derivatives are detailed.

Peripheral vasodilating agent containing piperidine derivative as active ingredient

The present invention relates to novel peripheral vasodilating agents characterized by each containing as an active ingredient, a piperidine derivative or pharmaceutically acceptable salt thereof having excellent peripheral vasodilating activity. Said pip